1. Uncommon low-grade brain tumors
- Author
-
Amos Burke, Sarah Jefferies, Kieren Allinson, Fiona Harris, Justin Cross, Thankamma Ajithkumar, Gail Horan, Stephen J. Price, Naduni Imbulgoda, and Elliott Rees
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Central nervous system ,Reviews ,medicine.disease_cause ,Proto-Oncogene Mas ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Pathological ,Mutation ,biology ,business.industry ,Brain Neoplasms ,Combined Modality Therapy ,medicine.anatomical_structure ,Apoptosis ,030220 oncology & carcinogenesis ,biology.protein ,Tumor necrosis factor alpha ,Neurology (clinical) ,Neoplasm Grading ,business ,Adjuvant ,030217 neurology & neurosurgery ,Platelet-derived growth factor receptor - Abstract
The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% of tumors) low-grade (grades I-II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the primary treatment. Adjuvant treatments, though their exact role is unknown, may be considered individually based on pathological subtypes and a proper assessment of risks and benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), and PDGFR (platelet derived growth factor receptor) have promising roles in future management.
- Published
- 2018